PCSK9 and atherosclerosis: Several recent trials have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies to statin therapy provides a further reduction in ASCVD risk, which is positively correlated with the incrementally achieved absolute LDL-C reduction (Giugliano et al., 2017, 2018; Schwartz et al., 2018; Koskinas et al., 2019).